Research
Hormonal
SGLT2 inhibitors (specifically enavogliflozin and sotagliflozin) provide superior glycemic control and cardiovascular/renal benefits compared to placebo or standard care in patients with type 2 diabetes, with sotagliflozin specifically indicated for heart failure.
If you have type 2 diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors like sotagliflozin or enavogliflozin. These oral drugs are now prioritized in guidelines because they protect your heart and kidneys while lowering blood sugar.
GoodSupportsHIGH confidence
Sotagliflozin is a new drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of heart failure with preserved and reduced ejection fraction. The mechanism involves inhibiting both SGLT1 and SGLT2...
Why this rating
Based on multiple Phase 3 clinical trials (ENHANCE-A, SCORED, SOLOIST-WHF) cited in the paper.
Source
Characteristics of the Latest Therapeutic Agent for Diabetes
Nuri Yun · Journal of Korean Diabetes · 2023
DOI 10.4093/jkd.2023.24.3.148
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (specifically semaglutide and tirzepatide) offer superior glycemic control and significant weight loss compared to other antidiabetic drugs, with tirzepatide showing potential for diabetes remission.Strong
- Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces the risk of heart failure and kidney disease progression in patients with chronic kidney disease and type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →